8-K: Tenaya Reports Q3 2025 Results, Gene Therapy Updates

Tenaya Therapeutics announced its third-quarter 2025 financial results and provided updates on its lead gene therapy programs, TN-201 and TN-401, including a clinical hold on MyPEAK-1.

Summary

• Reported third-quarter 2025 financial results, including a net loss of $20.3 million, an improvement from $25.6 million in Q3 2024.
• Cash, cash equivalents, and investments totaled $56.3 million as of September 30, 2025, with a projected runway into the second half of 2026.
• Presented new data from the MyPEAK-1 clinical trial of TN-201 for MYBPC3-associated HCM at the American Heart Association Scientific Sessions, showing consistent, deeper, and durable improvement in hypertrophy for Cohort 1 patients.
• Initial Cohort 2 data for TN-201 demonstrated early dose-responsive increases in TN-201 transduction and MyBP-C protein expression.
• The MyPEAK-1 clinical trial for TN-201 is currently on clinical hold as Tenaya prepares a protocol amendment related to patient monitoring and immunosuppressive regimens, though the company does not expect this to impact data milestones or development timelines.
• Completed dosing in Cohort 2 of the RIDGE-1 trial of TN-401 for PKP2-associated ARVC, with Cohort 1 data expected before year-end 2025.
• Independent Data Safety Monitoring Boards (DSMBs) provided positive recommendations for both TN-201 and TN-401 to advance into dose expansion cohorts, reflecting confidence in their emerging safety profiles.
• Published results from a seroprevalence study indicating that nearly 95% of MYBPC3-associated HCM patients would be eligible for AAV9 gene therapy based on low pre-existing immunity.
• Presented interim data from the MyClimb natural history study of pediatric MYBPC3-associated HCM, highlighting the severe risks faced by this patient population and identifying Left Ventricular Mass Index (LVMI) as a potential surrogate marker of treatment efficacy.

Sentiment

Score: 5

Explanation: The positive clinical data and DSMB recommendations for both lead programs are strong positives, indicating scientific progress. However, the clinical hold on the MyPEAK-1 trial introduces a significant element of uncertainty and risk, balancing out the positive developments. The reduced financial burn is good, but the company remains in a net loss position.

Positives

• Reduced net loss to $20.3 million in Q3 2025 from $25.6 million in Q3 2024.
• Decreased R&D expenses to $15.4 million in Q3 2025 from $20.4 million in Q3 2024, reflecting cost savings.
• Decreased G&A expenses to $5.6 million in Q3 2025 from $6.4 million in Q3 2024.
• Cash runway extended into the second half of 2026, providing financial stability for ongoing operations.
• Positive safety profiles for TN-201 and TN-401, with DSMBs recommending advancement to dose expansion cohorts.
• TN-201 showed consistent, deeper, and durable improvement in measures of hypertrophy for Cohort 1 patients at 52-weeks of follow-up.
• Initial TN-201 Cohort 2 data demonstrated early dose-responsive increases in TN-201 transduction and MyBP-C protein expression.
• Completed dosing in Cohort 2 of the RIDGE-1 trial for TN-401.
• Seroprevalence study indicated high patient eligibility (nearly 95% below Nab titers of 1:80) for AAV9 gene therapy in MYBPC3-associated HCM.
• MyClimb natural history study identified LVMI as a potential surrogate marker for treatment efficacy in MYBPC3-associated HCM.
• Presented new preclinical data showing significant and durable improvement of cardiac function in a pig model of ischemic heart failure using a proprietary in vivo reprogramming cocktail.
• Published a paper in JACC highlighting the potential benefit of decreased MTSS1 expression in dilated cardiomyopathy.

Negatives

• The MyPEAK-1 clinical trial for TN-201 is currently on clinical hold, which, despite company statements, introduces uncertainty and potential delays.
• The company continues to operate at a net loss of $20.3 million for the quarter.
• Cash, cash equivalents, and marketable securities decreased to $56.3 million as of September 30, 2025, from $61.4 million as of December 31, 2024.

Risks

• Availability of data at referenced times may differ from expectations.
• Timing and progress of clinical trials are subject to uncertainties.
• Unexpected concerns may arise from adverse safety events in clinical trials.
• Product candidates may fail to demonstrate safety and/or efficacy in clinical testing.
• Clinical trial results may differ from preclinical, interim, preliminary, topline, or expected results.
• Risks associated with discovering, developing, and commercializing safe and effective human therapeutics.
• Ability to develop, initiate, or complete preclinical studies and clinical trials, and obtain approvals for product candidates.
• Continuing compliance with applicable legal and regulatory requirements.
• Impact of any restructuring plan on the business.
• Ability to raise any additional funding needed to pursue business and product development plans.
• Reliance on third parties for various aspects of operations.
• Manufacturing, commercialization, and marketing capabilities and strategy.
• Loss of key scientific or management personnel.
• Competition in the industry.
• Ability to comply with specified operating covenants and restrictions in loan agreements.
• Ability to obtain and maintain intellectual property protection for product candidates.
• General economic and market conditions.

Future Outlook

The company expects its current funds to support planned operations into the second half of 2026. It anticipates sharing initial safety and biopsy data from the RIDGE-1 trial's Cohort 1 before year-end 2025. Despite a clinical hold on the MyPEAK-1 trial, the company does not expect it to impact data milestones or development timelines for TN-201. Management looks forward to advancing its lead gene therapy programs, TN-201 and TN-401, to provide transformative treatments for genetic cardiomyopathies.

Management Comments

• "Throughout the third quarter, we made important steps advancing our two lead gene therapy programs to provide transformative treatments to patients with serious genetic cardiomyopathies." Faraz Ali, CEO.
• "TN-201 and TN-401 each received positive recommendations from their respective Data Safety Monitoring Boards to advance into the dose expansion cohorts reflecting confidence in each product's emerging safety profile." Faraz Ali, CEO.
• "We were particularly pleased with the positive safety and promising clinical data presented on TN-201 as a potential treatment for MYBPC3-associated HCM at the recent AHA Scientific Sessions." Faraz Ali, CEO.
• "We also look forward to sharing meaningful safety and interim biopsy and efficacy data from the RIDGE-1 trial of TN-401 for patients with PKP2-associated ARVC in the coming weeks." Faraz Ali, CEO.

Industry Context

Tenaya Therapeutics operates in the highly specialized and competitive field of gene therapy for heart disease, a sector characterized by significant unmet medical needs and high development costs. The focus on genetic cardiomyopathies like MYBPC3-associated HCM and PKP2-associated ARVC positions Tenaya at the forefront of precision medicine for cardiovascular conditions. The positive DSMB recommendations for TN-201 and TN-401, along with promising clinical data, align with the broader industry trend of advancing gene therapies into later-stage development. The clinical hold on MyPEAK-1, while a setback, is not uncommon in early-stage gene therapy trials, reflecting the stringent regulatory environment and the need for careful protocol refinement, especially concerning patient monitoring and immunosuppression, which are critical aspects of AAV-based therapies. The company's research into cardiac regeneration and novel target identification (MTSS1) also reflects a broader industry push towards innovative approaches beyond traditional pharmacological interventions for heart failure.

Comparison to Industry Standards

• The seroprevalence study finding that nearly 95% of MYBPC3-associated HCM patients would be below Nab titers of 1:80 is a positive comparison against the typical maximum allowable AAV9 titer threshold in gene therapy trials, suggesting a broad eligible patient population.
• The MyClimb natural history study is believed to be the largest natural history study evaluating pediatric MYBPC3-associated HCM patients, providing a significant benchmark for understanding disease progression in this specific population.
• The positive recommendations from the Data Safety Monitoring Boards (DSMBs) for both TN-201 and TN-401 to advance into dose expansion cohorts indicate that their emerging safety profiles are considered acceptable by independent experts, which is a standard positive milestone in clinical development.
• The clinical hold on MyPEAK-1, while a negative, is not an anomaly in the gene therapy space, where FDA scrutiny on safety and protocol optimization is high, especially for novel treatments. This reflects the industry's rigorous regulatory standards.

Stakeholder Impact

• Shareholders: Potential for increased volatility due to the clinical hold, but also potential for long-term value creation if clinical programs succeed. Reduced net loss and extended cash runway offer some financial stability.
• Patients (MYBPC3-associated HCM & PKP2-associated ARVC): Hope for new transformative treatments, but the clinical hold on TN-201 introduces a delay in potential access to therapy.
• Employees: Continued focus on R&D and clinical development, with cost savings realized from prior spending reductions.
• Regulatory Authorities (FDA): Active engagement with the company regarding clinical trial protocols and safety.

Next Steps

• Work swiftly and collaboratively with the FDA to resolve the clinical hold on MyPEAK-1.
• Implement protocol changes at MyPEAK-1 trial sites to resume dosing.
• Share initial safety and biopsy data from RIDGE-1 Cohort 1 before year-end 2025.
• Continue advancing TN-201 and TN-401 into dose expansion cohorts.
• Continue preclinical development of programs like cardiac regeneration and MTSS1 modulation.
• Host a conference call on November 10, 2025, at 8:00 a.m. ET/5:00 a.m. PT to discuss TN-201 data and MyPEAK-1 status.

Key Dates

Recommendation

The filing presents a mixed bag of news. On one hand, the positive clinical data for TN-201 and the advancement of both lead gene therapy programs (TN-201 and TN-401) into dose expansion cohorts are strong indicators of scientific progress and potential. The reduced net loss and extended cash runway also provide some financial stability. However, the clinical hold on the MyPEAK-1 trial for TN-201 introduces significant uncertainty and potential delays, even if the company states otherwise. This regulatory setback, combined with the inherent high-risk nature of clinical-stage gene therapy development, warrants a cautious approach. Investors should hold to monitor the resolution of the clinical hold and the upcoming data release for TN-401, as these events will be crucial in determining the company's near-term trajectory.

Keywords

gene therapy, heart disease, cardiomyopathy, MYBPC3-associated HCM, PKP2-associated ARVC, TN-201, TN-401, clinical trial, biotechnology, cardiac regeneration, AAV9, hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, financial results, Q3 2025, clinical hold, FDA